Narsoplimab for adult TA-TMA

Sergio A. Giralt, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, explores the use of narsoplimab, an investigational MASP-2 inhibitor, currently evaluated for the treatment of adult transplant-associated thrombotic microangiopathy (TA-TMA). Recent studies have highlighted the efficacy of narsoplimab against TA-TMA, and Prof. Giralt discusses the promise of this agent. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

• #education
• #speaker_sergio_giralt
• #institution_memorial_sloan_kettering_cancer_center
• #event_vjvirtual
• #event_tct_2021
• #format_interview
• #subject_general
• #field_transplantation
• #medicines_narsoplimab
• #field_treatment
• #field_perspectives